SDZ Stock Overview
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Sandoz Group AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF30.00 |
| 52 Week High | CHF31.62 |
| 52 Week Low | CHF22.70 |
| Beta | 0 |
| 1 Month Change | 12.78% |
| 3 Month Change | 2.85% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 23.20% |
Recent News & Updates
Shareholder Returns
| SDZ | CH Pharmaceuticals | CH Market | |
|---|---|---|---|
| 7D | 1.7% | 2.1% | 0.4% |
| 1Y | n/a | 8.9% | -3.1% |
Return vs Industry: Insufficient data to determine how SDZ performed against the Swiss Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how SDZ performed against the Swiss Market.
Price Volatility
| SDZ volatility | |
|---|---|
| SDZ Average Weekly Movement | 4.2% |
| Pharmaceuticals Industry Average Movement | 3.0% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in CH Market | 7.2% |
| 10% least volatile stocks in CH Market | 2.0% |
Stable Share Price: SDZ has not had significant price volatility in the past 3 months.
Volatility Over Time: SDZ's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1886 | 22,633 | Richard Saynor | www.sandoz.com |
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms.
Sandoz Group AG Fundamentals Summary
| SDZ fundamental statistics | |
|---|---|
| Market cap | CHF12.89b |
| Earnings (TTM) | CHF70.36m |
| Revenue (TTM) | CHF9.12b |
183.2x
P/E Ratio1.4x
P/S RatioIs SDZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SDZ income statement (TTM) | |
|---|---|
| Revenue | US$9.98b |
| Cost of Revenue | US$5.42b |
| Gross Profit | US$4.56b |
| Other Expenses | US$4.49b |
| Earnings | US$77.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.18 |
| Gross Margin | 45.74% |
| Net Profit Margin | 0.77% |
| Debt/Equity Ratio | 49.2% |
How did SDZ perform over the long term?
See historical performance and comparison